Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy

BACKGROUND: Current clinical biomarkers for the programmed cell death 1 (PD-1) blockade therapy are insufficient because they rely only on the tumor properties, such as programmed cell death ligand 1 expression frequency and tumor mutation burden. Identifying reliable, responsive biomarkers based on...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JCI Insight
Asıl Yazarlar: Hatae, Ryusuke, Chamoto, Kenji, Kim, Young Hak, Sonomura, Kazuhiro, Taneishi, Kei, Kawaguchi, Shuji, Yoshida, Hironori, Ozasa, Hiroaki, Sakamori, Yuichi, Akrami, Maryam, Fagarasan, Sidonia, Masuda, Izuru, Okuno, Yasushi, Matsuda, Fumihiko, Hirai, Toyohiro, Honjo, Tasuku
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2020
Konular:
Clinical Medicine
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098729/
https://ncbi.nlm.nih.gov/pubmed/31855576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.133501
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller